NASDAQ:ANIK Anika Therapeutics (ANIK) Stock Forecast, Price & News $27.27 +0.55 (+2.06%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$26.61▼$27.5150-Day Range$25.16▼$28.8652-Week Range$20.12▼$32.51Volume81,054 shsAverage Volume63,064 shsMarket Capitalization$402.51 millionP/E RatioN/ADividend YieldN/APrice Target$29.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Anika Therapeutics MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside8.2% Upside$29.50 Price TargetShort InterestBearish3.04% of Shares Sold ShortDividend StrengthN/ASustainability-1.83Upright™ Environmental ScoreNews Sentiment1.12Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.13) to ($0.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.49 out of 5 starsMedical Sector894th out of 983 stocksSurgical & Medical Instruments Industry87th out of 97 stocks 1.0 Analyst's Opinion Consensus RatingAnika Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.50, Anika Therapeutics has a forecasted upside of 8.2% from its current price of $27.27.Amount of Analyst CoverageAnika Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.04% of the outstanding shares of Anika Therapeutics have been sold short.Short Interest Ratio / Days to CoverAnika Therapeutics has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Anika Therapeutics has recently increased by 3.82%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAnika Therapeutics does not currently pay a dividend.Dividend GrowthAnika Therapeutics does not have a long track record of dividend growth. Previous Next 3.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAnika Therapeutics has received a 45.27% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic bone grafts", "Medical splints", and "Nonwoven medical wipes" products. See details.Environmental SustainabilityThe Environmental Impact score for Anika Therapeutics is -1.83. Previous Next 3.4 News and Social Media Coverage News SentimentAnika Therapeutics has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Anika Therapeutics this week, compared to 3 articles on an average week.Search Interest1 people have searched for ANIK on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Anika Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anika Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.03% of the stock of Anika Therapeutics is held by insiders.Percentage Held by Institutions91.57% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Anika Therapeutics are expected to grow in the coming year, from ($1.13) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anika Therapeutics is -17.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anika Therapeutics is -17.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnika Therapeutics has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Anika Therapeutics (NASDAQ:ANIK) StockAnika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.Read More Receive ANIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIK Stock News HeadlinesMay 31, 2023 | msn.comStephens & Co. Reiterates Anika Therapeutics (ANIK) Equal-Weight RecommendationMay 30, 2023 | finance.yahoo.comAnika Completes Enrollment in Hyalofast® U.S. Pivotal Phase III Study Achieving Key MilestoneJune 3, 2023 | Vantage Point (Ad)We Called (ARWR) In Advance, Which Stocks Are Next?Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE. May 25, 2023 | americanbankingnews.comAssure (NASDAQ:IONM) vs. Anika Therapeutics (NASDAQ:ANIK) Head-To-Head ReviewMay 19, 2023 | americanbankingnews.comAnika Therapeutics (NASDAQ:ANIK) Now Covered by Analysts at StockNews.comMay 17, 2023 | marketwatch.comHemostatic Agents Market Research | 2023-2030May 16, 2023 | finance.yahoo.comGlobal Osteoarthritis Therapeutics Market to Reach $15.8 Billion by 2030May 16, 2023 | seekingalpha.comANIK Anika Therapeutics, Inc.June 3, 2023 | Vantage Point (Ad)We Called (ARWR) In Advance, Which Stocks Are Next?Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE. May 16, 2023 | americanbankingnews.comShort Interest in Anika Therapeutics, Inc. (NASDAQ:ANIK) Decreases By 6.1%May 15, 2023 | marketwatch.comInjectable Hyaluronic Acid Fillers Market: 2023-2030 RevenueMay 14, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Anika Therapeutics, Inc. (NASDAQ:ANIK) Reduced by Barrington ResearchMay 12, 2023 | marketwatch.comHyaluronic Acid Products Market Price & News with Size ForecastMay 11, 2023 | marketwatch.com2023 Arthritis Pain Injection Drug Market Size and Competitor Analysis in Medical Care Sector | with [104 Pages] and Forecast till 2031May 11, 2023 | markets.businessinsider.comBarrington Keeps Their Hold Rating on Anika Therapeutics (ANIK)May 11, 2023 | marketwatch.com2023-2029 Adhesion Barrier Gel Market Growth Prospects and Countries Analysis | with 85 PagesMay 10, 2023 | finanznachrichten.deAnika Therapeutics Inc.: Anika Reports First Quarter 2023 Financial ResultsMay 9, 2023 | msn.comRecap: Anika Therapeutics Q1 EarningsMay 9, 2023 | finance.yahoo.comAnika Therapeutics (ANIK) Reports Q1 Loss, Tops Revenue EstimatesMay 9, 2023 | finance.yahoo.comAnika Reports First Quarter 2023 Financial ResultsMay 5, 2023 | marketwatch.comBiomaterials Market Analysis and Forecast to 2031May 2, 2023 | marketwatch.com2023-2030 Hyaluronic Acid (HA) Raw Material Market Growth Developments with Latest UpdatesApril 29, 2023 | marketwatch.comCross-linked Hyaluronic Acid Market Demand by 2031April 28, 2023 | marketwatch.com8-K: Anika Therapeutics, Inc.April 28, 2023 | marketwatch.comBiological Bone Repair Materials Market Complete Overview till 2030April 27, 2023 | marketwatch.comBiomaterials Market Overview and Scope By 2030April 26, 2023 | marketwatch.comOrthopedic Hyaluronic Acid Market Complete Overview till 2031See More Headlines ANIK Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANIK Company Calendar Last Earnings3/06/2023Today6/03/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:ANIK CUSIP03525510 CIK898437 Webwww.anikatherapeutics.com Phone(781) 457-9000Fax781-305-9720Employees297Year Founded1992Price Target and Rating Average Stock Price Forecast$29.50 High Stock Price Forecast$31.00 Low Stock Price Forecast$28.00 Forecasted Upside/Downside+8.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,860,000.00 Net Margins-14.15% Pretax Margin-17.18% Return on Equity-3.77% Return on Assets-3.08% Debt Debt-to-Equity RatioN/A Current Ratio5.59 Quick Ratio4.15 Sales & Book Value Annual Sales$156.24 million Price / Sales2.58 Cash Flow$0.52 per share Price / Cash Flow52.58 Book Value$18.81 per share Price / Book1.45Miscellaneous Outstanding Shares14,760,000Free Float14,310,000Market Cap$402.51 million OptionableOptionable Beta0.84 Social Links Key ExecutivesCheryl Renee BlanchardPresident, Chief Executive Officer & DirectorAnne NunesVice President-OperationsMichael L. LevitzChief Financial Officer, Treasurer & EVPMira LeiwantVP-Quality, Regulatory & Clinical AffairsSteven W. EkVice President-Research & DevelopmentKey CompetitorsCerusNASDAQ:CERSOraSure TechnologiesNASDAQ:OSURUtah Medical ProductsNASDAQ:UTMDAtrionNASDAQ:ATRIAngioDynamicsNASDAQ:ANGOView All CompetitorsInstitutional OwnershipAmeriprise Financial Inc.Bought 26,258 shares on 5/22/2023Ownership: 1.411%JPMorgan Chase & Co.Bought 3,672 shares on 5/18/2023Ownership: 0.101%New York State Common Retirement FundSold 3,988 shares on 5/18/2023Ownership: 0.049%Thrivent Financial for LutheransSold 7,470 shares on 5/17/2023Ownership: 0.190%Geode Capital Management LLCBought 9,043 shares on 5/16/2023Ownership: 1.929%View All Institutional Transactions ANIK Stock - Frequently Asked Questions Should I buy or sell Anika Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ANIK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANIK, but not buy additional shares or sell existing shares. View ANIK analyst ratings or view top-rated stocks. What is Anika Therapeutics' stock price forecast for 2023? 2 brokers have issued 12 month target prices for Anika Therapeutics' stock. Their ANIK share price forecasts range from $28.00 to $31.00. On average, they predict the company's stock price to reach $29.50 in the next twelve months. This suggests a possible upside of 8.2% from the stock's current price. View analysts price targets for ANIK or view top-rated stocks among Wall Street analysts. How have ANIK shares performed in 2023? Anika Therapeutics' stock was trading at $29.60 at the start of the year. Since then, ANIK stock has decreased by 7.9% and is now trading at $27.27. View the best growth stocks for 2023 here. When is Anika Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our ANIK earnings forecast. How were Anika Therapeutics' earnings last quarter? Anika Therapeutics, Inc. (NASDAQ:ANIK) issued its quarterly earnings data on Monday, March, 6th. The biotechnology company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.06. The biotechnology company had revenue of $39.62 million for the quarter, compared to the consensus estimate of $38.32 million. Anika Therapeutics had a negative net margin of 14.15% and a negative trailing twelve-month return on equity of 3.77%. What ETFs hold Anika Therapeutics' stock? ETFs with the largest weight of Anika Therapeutics (NASDAQ:ANIK) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), Royce Quant Small-Cap Quality Value ETF (SQLV), Syntax Stratified SmallCap ETF (SSLY), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).Vanguard U.S. Minimum Volatility ETF (VFMV) and What guidance has Anika Therapeutics issued on next quarter's earnings? Anika Therapeutics updated its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $158.00 million-$163.00 million, compared to the consensus revenue estimate of $161.06 million. What other stocks do shareholders of Anika Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND). What is Anika Therapeutics' stock symbol? Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK." Who are Anika Therapeutics' major shareholders? Anika Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.67%), Trigran Investments Inc. (10.85%), Dimensional Fund Advisors LP (6.64%), State Street Corp (6.23%), Caligan Partners LP (4.85%) and Renaissance Technologies LLC (3.90%). Insiders that own company stock include Cheryl R Blanchard, David Colleran, James Loerop, Jeffery S Thompson, John B Henneman III, Michael L Levitz and Raymond J Land. View institutional ownership trends. How do I buy shares of Anika Therapeutics? Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Anika Therapeutics' stock price today? One share of ANIK stock can currently be purchased for approximately $27.27. How much money does Anika Therapeutics make? Anika Therapeutics (NASDAQ:ANIK) has a market capitalization of $402.51 million and generates $156.24 million in revenue each year. The biotechnology company earns $-14,860,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. How many employees does Anika Therapeutics have? The company employs 297 workers across the globe. How can I contact Anika Therapeutics? Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.anikatherapeutics.com. The biotechnology company can be reached via phone at (781) 457-9000, via email at investorrelations@anikatherapeutics.com, or via fax at 781-305-9720. This page (NASDAQ:ANIK) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anika Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.